Journal of Urgent Care Medicine

Two-Dose Shingles Vaccine Shows Long-Term Effectiveness

A real-world study published in Clinical Infectious Diseases found that two doses of the adjuvanted recombinant shingles vaccine was estimated to be 74% effective at preventing herpes zoster (HZ) and 84% effective at preventing postherpetic neuralgia (PHN) in U.S. adults aged 50 years and older. The study, conducted by researchers from Kaiser Permanente Southern California (KPSC) in collaboration with the vaccine’s manufacturer GSK, evaluated the long-term effectiveness of the recombinant zoster vaccine. Researchers followed participants …

Guidelines Push for More Patients to Receive Shingles Vaccinations

Patients in the 50- to 59-year-old age range should receive vaccination against shingles, according to the latest recommendation from the Advisory Committee on Immunization Practices (ACIP). That guidance accompanied a rare—and nearly evenly split—nod to one vaccine over another. In an 8-7 vote, ACIP recommended the recently approved Shingrix (GlaxoSmithKline) over Zostavex (Merck). Both vaccines are FDA-approved for use in patients 50 and over, but ACIP recommends Zostavex only in patients over the age of …

Login to JUCM